

Resource Summary Report

Generated by [dkNET](#) on Sep 12, 2026

DD-Cas9 with filler sequence and Venus (EDCPV)

RRID:Addgene_90085

Type: Plasmid

Proper Citation

RRID:Addgene_90085

Plasmid Information

URL: <http://www.addgene.org/90085>

Proper Citation: RRID:Addgene_90085

Insert Name: Cas9

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:28224990](#)

Vector Backbone Description: Backbone Marker:Addgene; Vector Backbone:lentiCRISPR v2; Vector Types:Mammalian Expression, Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: DD-Cas9 with filler sequence and Venus (EDCPV)

Record Creation Time: 20220422T222611+0000

Record Last Update: 20260912T093354+0000

Ratings and Alerts

No rating or validation information has been found for DD-Cas9 with filler sequence and Venus (EDCPV).

No alerts have been found for DD-Cas9 with filler sequence and Venus (EDCPV).

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Anand JR, et al. (2025) TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. *NAR cancer*, 7(1), zcaf009.

Anand JR, et al. (2025) TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. *bioRxiv : the preprint server for biology*.

Marohl T, et al. (2025) PCSK5M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells. *bioRxiv : the preprint server for biology*.

Marohl T, et al. (2025) PCSK5M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells. *Molecular cancer research : MCR*.

Hsieh HC, et al. (2024) PRMT-7/PRMT7 activates HLH-30/TFEB to guard plasma membrane integrity compromised by bacterial pore-forming toxins. *Autophagy*, 20(6), 1335.

Przanowska RK, et al. (2024) Patient-derived response estimates from zero-passage organoids of luminal breast cancer. *bioRxiv : the preprint server for biology*.

Przanowska RK, et al. (2024) Patient-derived response estimates from zero-passage organoids of luminal breast cancer. *Breast cancer research : BCR*, 26(1), 192.

Lee YS, et al. (2023) VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. *Genes & cancer*, 14, 30.

Leung AO, et al. (2022) Targeting G-quadruplex for rescuing impaired chondrogenesis in WRN-deficient stem cells. *Cell & bioscience*, 12(1), 212.

Schrempf A, et al. (2022) POL η processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells. *Cell reports*, 41(9), 111716.

Šafari? Tepeš P, et al. (2021) A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization. *Journal of visualized experiments : JoVE*(175).

Bosch-Guiteras N, et al. (2021) Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. *Genome research*, 31(3), 461.

Feng W, et al. (2019) Genetic determinants of cellular addiction to DNA polymerase theta. *Nature communications*, 10(1), 4286.

Lakoduk AM, et al. (2019) Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration. *The Journal of cell biology*, 218(6), 1928.